Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

GATC Biotech AG. (6/9/16). "Press Release: Liquid Biopsy Test – GATCLiquid OncoTarget – Expanded to Cover Blood Cancers such as Acute Myeloid Leukaemia". Constance.

Organisation Organisation GATC Biotech AG
  Today Eurofins Genomics Europe Sequencing GmbH
  Group Eurofins (Group)
Product Product GATCLiquid OncoTarget services
Person Person Paprotka, Tobias (GATC Biotech 201211 Head of Development)
     


GATCLIQUID ONCOTARGET for cost-efficient profiling of most important tumor-specific mutation in an individual cancer case

> Worldwide unique service for highly sensitive profiling of the most relevant mutations for detection and management of non-small cell lung cancer (NSCLC), melanoma, colorectal and other difficult to detect cancers

> Non-invasive analysis of so far 12 actionable genomic alterations in circulating cell-free DNA for cost-efficient treatment monitoring and early detection of cancer relapse


GATC Biotech, a world-wide leading provider of innovative sequencing and diagnostic solutions, announced today the immediate expansion of the company’s liquid biopsy service: GATCLIQUID ONCOTARGET. With a simple blood draw, sensitive detection of blood cancers, such as acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPNs) in addition to melanoma, lung, colorectal and pancreatic cancers through analysis of actionable mutations in circulating tumour DNA (ctDNA) is now enabled. The service reliably profiles 12 cancer genomic alterations so far.

The continuously expanding target list makes GATCLIQUID ONCOTARGET suitable for detection and regular monitoring of various cancers that are difficult to characterise with conventional diagnostic procedures.

“GATCLIQUID ONCOTARGET is now applicable to various rare and common cancers types such as NSCLC, pancreas, colorectal cancer, melanoma and blood cancer such as AML or MPNs,” said Dr Tobias Paprotka, Director of R&D at GATC Biotech. “Increasing the number of mutational targets that can be analysed with very high sensitivity strongly supports our mission of advancing cancer precision care. With cost-efficient surveillance of the most relevant mutation in a specific cancer case, we hope to support oncologists in finding the most suitable therapy for each individual patient. We will achieve this by providing clinicians the means to closely evaluate the efficacy of the patient’s treatment course and to react promptly to the emergence of any treatment resistance.”

The new target set has been established in close collaboration with specialised clinical researchers to profile additional hotspot mutations in established cancer biomarkers like NRAS and EGFR. The list encompasses genomic alterations in more than the usual suspects in cancer development, such as BRAF, KRAS and EGFR. Clinically actionable mutations can now be analysed in key cancer drivers including JAK2, IDH1, NRAS and c-KIT.

The droplet digital PCR test offers detection of genomic alterations with a sensitivity as low as 0.1%. Proprietary workflows and cutting-edge technologies together enable precise quantification of low-level mutations during treatment, as well as detection of cancer recurrence often prior to clinical progression. GATC Biotech has already teamed up with expert cancer researchers to continuously grow the list of targeted actionable mutations to improve cancer patient outcomes.

“In the following weeks, we will enhance the world’s only research service for real-time profiling of tumour characteristics by adding another target set with even more key cancer drivers that are important for reliable, non-invasive cancer management,” concluded Dr Paprotka.


About GATCLIQUID

Our liquid biopsy-based service family offers cancer characterisation from a simple blood sample. Painful and costly tissue biopsies are replaced by non-invasive analysis of circulating tumour DNA (ctDNA). This offers clinical researchers the opportunity to explore, screen and monitor a wide range of tumour-related mutations for close surveillance of tumour dynamics and cancer heterogeneity in individual patients.

Depending on specific requirements, the GATC Biotech research service offers:
ONCOEXOME - Unbiased overview of all mutations in protein coding regions
ONCOPANEL - Targeted screening for key cancer drivers
ONCOTARGET - Ultra-sensitive monitoring of the most important mutation

GATC Biotech, a family owned business since 1990, is Europe’s leading sequencing services provider with more than 10,000 customers from academia, healthcare and industry worldwide. The company consistently contributes to the sequencing field with innovative products, scientific expertise and rigorous quality.

Currently, the entrepreneurial energy is concentrated on a completely new approach in the area of personalised medicine. GATCLIQUID is the world’s first liquid biopsy- based service for cancer research and diagnosis.

As a renowned brand, GATC Biotech offers all leading sequencing technologies in its own laboratories in Cologne and Constance, Germany. The company’s proprietary workflows deliver ready-for-diagnostics results backed by ISO 17025 accreditation and ISO 13485 certification. From Sanger to next-generation sequencing,

GATC Biotech offers unmatched flexibility to customers interested in any kind of genomics such as transcriptome, epigenome, exome or whole genome analysis.

GATC Biotech has a proven record of publicly funded projects by the EU and other national agencies. The company has formed numerous successful collaborations with world-renowned universities, academic institutions, pharmaceutical and biotechnological companies.

Please visit http://www.gatc-biotech.com/ for more information about genomic innovation – Made in Germany.

   
Record changed: 2016-06-13

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Eurofins (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px




» top